aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Evommune was founded with the mission to discover and develop novel therapies aimed at treating and halting the progression of chronic inflammatory diseases. The company employs a tissue-based approach to advance scientific insights and accelerate the development of transformative medicines. Their market focus is on creating a broad portfolio of best-in-class therapeutic options that target the root causes of inflammation.
Notable affiliated people include experts in immunology and drug development, though specific names are not provided. Evommune has achieved significant milestones, such as an expanded strategic collaboration with Maruho, a key player in dermatology. The company's impact lies in its innovative approach to addressing chronic inflammation, offering hope for improved treatments and quality of life for affected individuals.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Evommune founded?
Evommune was founded in 2020.
Where is Evommune’s headquarters located?
Evommune’s headquarters is located in Palo Alto, CA, US.
When was Evommune’s last funding round?
Evommune’s most recent funding round was for $7.5M (USD) in June 2023.
How many employees does Evommune have?
Evommune has 26 employees as of Feb 4, 2024.
How much has Evommune raised to-date?
As of July 05, 2023, Evommune has raised a total of $153M (USD) since Jun 28, 2023.
Add Comparison
Total Raised to Date
$153M
USD
Last Update Jun 28, 2023
Last Deal Details
$7.5M
USD
Jun 28, 2023
Series B
Total Employees Over Time
26
As of Feb 2024
Evommune Address
Palo Alto,
California
94306
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts